Yesafili is a VEGF inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), ...

This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

Worldwide, age-related macular degeneration (AMD) is the leading cause of severe vision loss in people aged 50 or older. Neovascular AMD is an advanced form of the condition, also known as “exudative ...

5. Jeremias S. FDA approves biosimilar Enzeevu for eye conditions. The Center for Biosimilars. August 12, 2024.

As the first-to-file interchangeable biosimilar to Eylea, Yesafili affirms our scientific strength and marks our strategic entry into Ophthalmology, expanding our footprint in the U.S. and ...

Regeneron's Eylea generated $4.77 billion in U.S. sales in 2024. There are five approved biosimilars for Eylea - Amgen's Pavblu, Sandoz's Enzeevu, Formycon's Ahzantive, Samsung Bioepis' Opuviz and ...

Two additional biosimilars that reference Eylea were approved in August 2024: Sandoz’s Enzeevu (aflibercept-abzv) and Amgen’s Pavblu (aflibercept-ayyh). Pavblu has already launched, despite ongoing ...

The aflibercept biosimilar, Enzeevu, is the fourth biosimilar referencing Eylea, having received approval in August 2024. 2 Enzeevu was granted interchangeability status, which allows it to be ...